tetano
Editor, Senior Moderator
Nat Immunol
. 2021 Aug 20.
doi: 10.1038/s41590-021-01021-0. Online ahead of print.
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
Kizzmekia S Corbett[SUP] 1 2 [/SUP], Anne P Werner[SUP] 1 [/SUP], Sarah O' Connell[SUP] 1 [/SUP], Matthew Gagne[SUP] 1 [/SUP], Lilin Lai[SUP] 3 [/SUP], Juan I Moliva[SUP] 1 [/SUP], Barbara Flynn[SUP] 1 [/SUP], Angela Choi[SUP] 4 [/SUP], Matthew Koch[SUP] 4 [/SUP], Kathryn E Foulds[SUP] 1 [/SUP], Shayne F Andrew[SUP] 1 [/SUP], Dillon R Flebbe[SUP] 1 [/SUP], Evan Lamb[SUP] 1 [/SUP], Saule T Nurmukhambetova[SUP] 1 [/SUP], Samantha J Provost[SUP] 1 [/SUP], Kevin W Bock[SUP] 5 [/SUP], Mahnaz Minai[SUP] 5 [/SUP], Bianca M Nagata[SUP] 5 [/SUP], Alex Van Ry[SUP] 6 [/SUP], Zackery Flinchbaugh[SUP] 6 [/SUP], Timothy S Johnston[SUP] 1 [/SUP], Elham Bayat Mokhtari[SUP] 1 [/SUP], Prakriti Mudvari[SUP] 1 [/SUP], Amy R Henry[SUP] 1 [/SUP], Farida Laboune[SUP] 1 [/SUP], Becky Chang[SUP] 6 [/SUP], Maciel Porto[SUP] 6 [/SUP], Jaclyn Wear[SUP] 6 [/SUP], Gabriela S Alvarado[SUP] 1 [/SUP], Seyhan Boyoglu-Barnum[SUP] 1 [/SUP], John-Paul M Todd[SUP] 1 [/SUP], Bridget Bart[SUP] 6 [/SUP], Anthony Cook[SUP] 6 [/SUP], Alan Dodson[SUP] 6 [/SUP], Laurent Pessaint[SUP] 6 [/SUP], Katelyn Steingrebe[SUP] 6 [/SUP], Sayda Elbashir[SUP] 4 [/SUP], Manjari Sriparna[SUP] 1 [/SUP], Andrew Pekosz[SUP] 7 [/SUP], Hanne Andersen[SUP] 6 [/SUP], Kai Wu[SUP] 4 [/SUP], Darin K Edwards[SUP] 4 [/SUP], Swagata Kar[SUP] 6 [/SUP], Mark G Lewis[SUP] 6 [/SUP], Eli Boritz[SUP] 1 [/SUP], Ian N Moore[SUP] 5 [/SUP], Andrea Carfi[SUP] 4 [/SUP], Mehul S Suthar[SUP] 3 8 [/SUP], Adrian McDermott[SUP] 1 [/SUP], Mario Roederer[SUP] 1 [/SUP], Martha C Nason[SUP] 9 [/SUP], Nancy J Sullivan[SUP] 1 [/SUP], Daniel C Douek[SUP] 1 [/SUP], Barney S Graham[SUP] 10 [/SUP], Robert A Seder[SUP] 11 [/SUP]
Affiliations
Abstract
B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or 100 µg of Moderna's mRNA-1273 vaccine, a single immunization of 30 µg, or no vaccine. Two doses of 100 µg of mRNA-1273 induced 50% inhibitory reciprocal serum dilution neutralizing antibody titers against live SARS-CoV-2 p.Asp614Gly and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. After challenge with B.1.351, there was ~4- to 5-log[SUB]10[/SUB] reduction of viral subgenomic RNA and low to undetectable replication in bronchoalveolar lavages in the two-dose vaccine groups, with a 1-log[SUB]10[/SUB] reduction in nasal swabs in the 100-µg group. These data establish that a two-dose regimen of mRNA-1273 will be critical for providing upper and lower airway protection against major variants of concern.
. 2021 Aug 20.
doi: 10.1038/s41590-021-01021-0. Online ahead of print.
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
Kizzmekia S Corbett[SUP] 1 2 [/SUP], Anne P Werner[SUP] 1 [/SUP], Sarah O' Connell[SUP] 1 [/SUP], Matthew Gagne[SUP] 1 [/SUP], Lilin Lai[SUP] 3 [/SUP], Juan I Moliva[SUP] 1 [/SUP], Barbara Flynn[SUP] 1 [/SUP], Angela Choi[SUP] 4 [/SUP], Matthew Koch[SUP] 4 [/SUP], Kathryn E Foulds[SUP] 1 [/SUP], Shayne F Andrew[SUP] 1 [/SUP], Dillon R Flebbe[SUP] 1 [/SUP], Evan Lamb[SUP] 1 [/SUP], Saule T Nurmukhambetova[SUP] 1 [/SUP], Samantha J Provost[SUP] 1 [/SUP], Kevin W Bock[SUP] 5 [/SUP], Mahnaz Minai[SUP] 5 [/SUP], Bianca M Nagata[SUP] 5 [/SUP], Alex Van Ry[SUP] 6 [/SUP], Zackery Flinchbaugh[SUP] 6 [/SUP], Timothy S Johnston[SUP] 1 [/SUP], Elham Bayat Mokhtari[SUP] 1 [/SUP], Prakriti Mudvari[SUP] 1 [/SUP], Amy R Henry[SUP] 1 [/SUP], Farida Laboune[SUP] 1 [/SUP], Becky Chang[SUP] 6 [/SUP], Maciel Porto[SUP] 6 [/SUP], Jaclyn Wear[SUP] 6 [/SUP], Gabriela S Alvarado[SUP] 1 [/SUP], Seyhan Boyoglu-Barnum[SUP] 1 [/SUP], John-Paul M Todd[SUP] 1 [/SUP], Bridget Bart[SUP] 6 [/SUP], Anthony Cook[SUP] 6 [/SUP], Alan Dodson[SUP] 6 [/SUP], Laurent Pessaint[SUP] 6 [/SUP], Katelyn Steingrebe[SUP] 6 [/SUP], Sayda Elbashir[SUP] 4 [/SUP], Manjari Sriparna[SUP] 1 [/SUP], Andrew Pekosz[SUP] 7 [/SUP], Hanne Andersen[SUP] 6 [/SUP], Kai Wu[SUP] 4 [/SUP], Darin K Edwards[SUP] 4 [/SUP], Swagata Kar[SUP] 6 [/SUP], Mark G Lewis[SUP] 6 [/SUP], Eli Boritz[SUP] 1 [/SUP], Ian N Moore[SUP] 5 [/SUP], Andrea Carfi[SUP] 4 [/SUP], Mehul S Suthar[SUP] 3 8 [/SUP], Adrian McDermott[SUP] 1 [/SUP], Mario Roederer[SUP] 1 [/SUP], Martha C Nason[SUP] 9 [/SUP], Nancy J Sullivan[SUP] 1 [/SUP], Daniel C Douek[SUP] 1 [/SUP], Barney S Graham[SUP] 10 [/SUP], Robert A Seder[SUP] 11 [/SUP]
Affiliations
- PMID: 34417590
- DOI: 10.1038/s41590-021-01021-0
Abstract
B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or 100 µg of Moderna's mRNA-1273 vaccine, a single immunization of 30 µg, or no vaccine. Two doses of 100 µg of mRNA-1273 induced 50% inhibitory reciprocal serum dilution neutralizing antibody titers against live SARS-CoV-2 p.Asp614Gly and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. After challenge with B.1.351, there was ~4- to 5-log[SUB]10[/SUB] reduction of viral subgenomic RNA and low to undetectable replication in bronchoalveolar lavages in the two-dose vaccine groups, with a 1-log[SUB]10[/SUB] reduction in nasal swabs in the 100-µg group. These data establish that a two-dose regimen of mRNA-1273 will be critical for providing upper and lower airway protection against major variants of concern.